Development and regulation of exosome-based therapy products

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Sep;8(5):744-57. doi: 10.1002/wnan.1395. Epub 2016 Feb 17.

Abstract

Recently, various innovative therapies involving the ex vivo manipulation and subsequent reintroduction of exosome-based therapeutics into humans have been developed and validated, although no exosome-based therapeutics have yet to be brought into the clinic. Exosomes are nanosized vesicles secreted by many cells that utilize them for cell-to-cell communications to facilitate transport of proteins and genetic material. Comprised of cellular membranes with multiple adhesive proteins on their surface, exosomes offer distinct advantages that exceptionally position them as highly effective drug carriers. Additionally, exosomes can exert unique biological activity reflective of their origin that may be used for therapy of various diseases. In fact, exosomes have benefits of both synthetic nanocarriers and cell-mediated drug delivery systems, and avoid their limitations. This concise review highlights the recent developments in exosome-based drug delivery systems and the main regulatory considerations for using this type of therapeutic in clinic. WIREs Nanomed Nanobiotechnol 2016, 8:744-757. doi: 10.1002/wnan.1395 For further resources related to this article, please visit the WIREs website.

Publication types

  • Review

MeSH terms

  • Animals
  • Cell- and Tissue-Based Therapy*
  • Drug Delivery Systems*
  • Exosomes*
  • Humans
  • Mice
  • Models, Biological
  • Nanomedicine
  • Nanoparticles*